Remarkably, this was well in agreement with survival curves of GBM patients across subtypes (n = 83 IDH1 wild-type GBM patients), in which proneural cases was shown to exhibit more lethal tumors (n = 13; median = 12 months), than the mesenchymal (n = 28; median = 13 months) and classical ones (n = 42; median = 19 months)(P = 0.0047, Log-rank test and P = 0.0186, Gehan-Breslow-Wilcoxon test) (Fig. 5E). This evidence concerns the gene IDH1 and glioblastoma.